Bioarchitech has officially filed a UK patent application, securing protection for our lead candidate virus BA-V151. 

BA-V151 inhibits CD47 locally within tumours and enables cells of the immune system to kill cancer cells more effectively, bypassing one of the key mechanisms that tumours use to resist immune surveillance and antibody therapy.

CD47 is a well validated immune checkpoint target with huge therapeutic potential across cancer indications but has been shown to be too toxic or ineffective when targeted systemically.

As we move through the application process we hope to achieve broad I.P protection in territories worldwide.

This milestone underscores our commitment to advancing the frontiers of immunotherapy and bringing transformative therapies closer to patients in need.